Dysbiosis News and Research

RSS

Dysbiosis is a condition caused by an imbalance in the bacterial community (microbiome) of the human gut. Dysbiosis disrupts the ecoystsem of the gut, resulting in symptoms such as diarrhea, constipation, bloating, and indigestion, among others.

Living in deprived neighborhoods reshapes the gut microbiome

This study reveals links between socioeconomic deprivation and gut microbiome changes, highlighting potential pathways to mental and metabolic health issues.

2 Mar 2026

Long-term cola intake weakens immune cell counts in controlled rat study

Replacing drinking water entirely with sugar-sweetened or sugar-free cola for eight weeks altered gut microbiota composition and immune-related indices in rats, despite no changes in body weight or blood glucose. Both beverages were associated with leukocyte reductions and organ-related biochemical shifts, with sugar-sweetened cola more strongly linked to renal markers and diet cola to elevated liver enzymes.

25 Feb 2026

New review explores whether berries can slow cognitive decline linked to obesity

This systematic review in Nutrients evaluates human studies investigating whether polyphenol-rich berry consumption can modulate obesity-related metabolic dysfunction and support cognitive performance, particularly in individuals at risk of mild cognitive impairment. Evidence suggests modest memory benefits and possible metabolic improvements, although biomarker findings and long-term clinical relevance remain uncertain.

22 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Gut bacteria patterns help predict insulin resistance in type 2 diabetes, study finds

Researchers used 16S rRNA sequencing and machine learning to identify gut microbiome patterns associated with insulin resistance severity in people with type 2 diabetes. XGBoost models showed that specific bacterial genera, including Bacteroides and Faecalibacterium, help distinguish individuals with higher insulin resistance from healthy controls.

19 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Advances in pathogenesis and management of gastrointestinal motility disorders

Announcing a new publication for Acta Materia Medica journal. Gastrointestinal motility disorders (GIMDs) are characterized by impaired gastrointestinal motility.

13 Feb 2026

Clear aligners protect oral microbiome better than fixed braces

Researchers compare the effects of clear aligners and fixed appliances on oral microbiota and oxidative stress in the oral cavity.

4 Feb 2026

Gut problems may shape Parkinson’s disease progression through the gut-brain axis

This narrative review examines how gastrointestinal dysfunction, gut dysbiosis, and altered gut-brain axis signaling are closely associated with the onset and progression of Parkinson’s disease. It synthesizes evidence supporting a possible bottom-up disease model while highlighting integrative, gut-targeted strategies as adjuncts to symptom management rather than proven disease-modifying therapies.

27 Jan 2026

Evidence links gut microbiome changes to Alzheimer’s progression

Human studies consistently report gut microbiome differences in mild cognitive impairment and Alzheimer’s disease, but findings vary widely by cohort, methods, and taxa. Heterogeneity and limited longitudinal data prevent causal inference, highlighting the need for functional profiling and well-designed intervention trials.

25 Jan 2026

Expert guidance on fecal microbiota transplantation in liver disease

The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT), an emerging therapeutic modality, has demonstrated promising potential in the treatment of chronic liver diseases.

22 Jan 2026

Chemotherapy-induced gut changes trigger anti-metastatic immune response

Chemotherapy commonly damages the intestinal lining, a well-known side effect. But this injury does not remain confined to the gut.

22 Jan 2026

Bacteria behind Nagashima-type palmoplantar keratosis foot odor identified

The distinct foot odor that comes with the skin disorder Nagashima-type palmoplantar keratosis (NPPK) is caused by the overgrowth of a specific bacterial strain.

22 Jan 2026

Cannabidiol could become a therapeutic tool for fetal alcohol spectrum disorder

Cannabidiol (CBD) could become a therapeutic tool to address some of the most frequent and disabling consequences of fetal alcohol spectrum disorder (FASD), a condition caused by alcohol exposure during pregnancy.

14 Jan 2026

Why promising microbiome therapies rarely work in patients

Addressing the microbiome's translational gap involves understanding biological complexity and developing function-driven, patient-specific interventions.

8 Jan 2026

Prebiotic microcapsules deliver pterostilbene to the colon to alleviate ulcerative colitis

A team led by clinicians and engineers has wrapped the plant-derived polyphenol pterostilbene (PSB) into prebiotic alginate/resistant-starch microcapsules coated with chitosan and shown that oral administration dampens dextran-sulfate-sodium (DSS) colitis in mice.

23 Dec 2025

How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOS

This review synthesizes evidence that gut microbiota dysbiosis contributes to insulin resistance and symptom severity in polycystic ovary syndrome through impaired barrier function, inflammation, and altered microbial metabolites. It evaluates how Traditional Chinese Medicine may modulate these pathways while highlighting major gaps in clinical validation, safety, and standardization.

16 Dec 2025

Unnecessary gluten-free diets may put children at risk

Understanding gluten-related disorders is crucial for pediatric nutrition, as gluten-free diets can pose health risks without appropriate medical supervision.

15 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.

8 Dec 2025